

# Clinical trials of mitiglinide

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

| Trial   | Treatments  | Patients  | Trials design and methods    |
|---|---|---|------------------------------|
| <b>mitiglinide+voglibose vs insulin glargine</b>                      |   |   |                              |
| <b>GLORIA</b><br>[NCT00663884]<br>n=NA<br>follow-up: 16 weeks         | combination therapy of 10 mg mitiglinide or 0.2mg voglibose versus insulin glargine               | diabetic patients whose glycemic control were not enough despite administration of oral antidiabetic drug or insulin glargine | open Korea                   |
| <b>mitiglinide vs nateglinide</b>                                     |   |   |                              |
| <b>Gao</b><br>[NCT00461617]<br>n=291<br>follow-up: 20 weeks           | mitiglinide 10 - 20 mg three times daily versus nateglinide 120 mg three times daily              | Chinese type 2 diabetes mellitus patients   | Parallel groups double-blind |
| <b>mitiglinide vs on top insulin glargine</b>                         |   |   |                              |
| <b>Kumashiro , 2007</b><br>n=NA<br>follow-up:                         | mitiglinide versus on top of once daily insulin glargine  | -   |                              |
| <b>mitiglinide vs placebo (add on MET)</b>                            |   |   |                              |
| <b>NCT01037842</b><br>[NCT01037842]<br>n=NA<br>follow-up: 16 weeks    | mitiglinide versus placebo  | patients with type 2 diabetes who show inadequate glycemic control with metformin monotherapy                                 | double-blind Korea           |
| <b>EX-1510-CT-003</b><br>[NCT00519142]<br>n=NA<br>follow-up: 24 weeks | metformin + mitiglinide three times a day with meals versus (metformin + placebo for mitiglinide) | patients with Type 2 diabetes mellitus not well controlled with metformin alone   | double-blind US              |
| <b>mitiglinide vs placebo (on top pioglitazone)</b>                   |   |   |                              |
| <b>Kaku , 2009</b><br>n=NA<br>follow-up: 16 weeks                     | additional mitiglinide 5 or 10 mg tid versus placebo on top pioglitazone                          | Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy                               | Parallel groups multicenter  |

More details and results :

- antidiabetic drugs for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q81>
- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>

- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - Meglitinides (glinides) for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q549>

## References

### **GLORIA, 0:**

#### **Gao, 0:**

Gao X, , Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res ;37:812-21. [19589264]

#### **Kumashiro, 2007:**

Kumashiro N, Yoshihara T, Kanazawa Y, Shimizu T, Watada H, Tanaka Y, Fujitani Y, Kawamori R, Hirose T, Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 2007;54:163-6. [17185877]

#### **NCT01037842, :**

#### **EX-1510-CT-003, 0:**

#### **Kaku, 2009:**

Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y, Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. Endocr J 2009;56:657-64. [19352048]

Entry terms: miti-glinide, KAD 1229, KAD-1229,